Weighing benefits and risks--the FDA's review of prasugrel

N Engl J Med. 2009 Sep 3;361(10):942-5. doi: 10.1056/NEJMp0907122.
No abstract available

MeSH terms

  • Angina, Unstable / drug therapy*
  • Angioplasty, Balloon, Coronary*
  • Aspirin / therapeutic use
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / mortality
  • Causality
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Coronary Thrombosis / prevention & control*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Hemorrhage / chemically induced*
  • Humans
  • Myocardial Infarction / drug therapy*
  • Neoplasms / epidemiology
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prasugrel Hydrochloride
  • Thiophenes / adverse effects
  • Thiophenes / therapeutic use*
  • United States
  • United States Food and Drug Administration

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Prasugrel Hydrochloride
  • Aspirin